Basis: FMP quote market capitalization / four-quarter operating cash flow. Source: stored company filings and market data; unavailable inputs remain N/A.
The Price/OCF ratio is N/A as of 2026-10-06T19:48:31.711Z.
Calculation as of: 2026-10-06T19:48:31.711Z.
Quote observation: 2026-10-06T19:44:48.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 5f972cfcdde9e4531ce3198b66662ffcb9080d57c966754dbe52ec7edaf14096
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PRICE/OCF RATIO
N/A
NervGen Pharma Corp. Common stock
Market Cap
$145.70M
Price/OCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$145.96M
Price/OCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$145.29M
Price/OCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$146.26M
Price/OCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$146.82M
Price/OCF Ratio
N/A
TTM Avg
11.71
3Y Avg
27.68
5Y Avg
23.05
Market Cap
$144.51M
Price/OCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$144.06M
Price/OCF Ratio
1.14
TTM Avg
4.90
3Y Avg
4.90
5Y Avg
4.90
Market Cap
$147.35M
Price/OCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | PRICE/OCF RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| NervGen Pharma Corp. Common stock (NGEN) | $145.70M | N/A | N/A | N/A | N/A |
| Anavex Life Sciences Corp. (AVXL)vs › | $145.96M | N/A | N/A | N/A | N/A |
| Protara Therapeutics, Inc. (TARA)vs › | $145.29M | N/A | N/A | N/A | N/A |
| Acumen Pharmaceuticals, Inc. (ABOS)vs › | $146.26M | N/A | N/A | N/A | N/A |
| Voyager Therapeutics, Inc. (VYGR)vs › | $146.82M | N/A | 11.71 | 27.68 | 23.05 |
| Korsana Biosciences, Inc. (KRSA)vs › | $144.51M | N/A | N/A | N/A | N/A |
| Fortress Biotech, Inc. (FBIOP)vs › | $144.06M | 1.14 | 4.90 | 4.90 | 4.90 |
| ALX Oncology Holdings Inc. (ALXO)vs › | $147.35M | N/A | N/A | N/A | N/A |
| Codexis, Inc. (CDXS)vs › | $147.36M | N/A | 32.64 | 32.64 | 32.64 |
| Nyxoah S.A. (NYXH)vs › | $143.10M | N/A | N/A | N/A | N/A |
P/OCF Ratio
N/A
P/FCF Ratio
N/A
P/OCF measures market price relative to operating cash flow: market cap divided by TTM operating cash flow. OCF is cash from operations before capital expenditures, so it sits above free cash flow — P/OCF typically reads below P/FCF, with the widest gap for capex-heavy businesses.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
